Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Ivermectin in Mild COVID-19 (SILVERBULLET)
NCT04407507Phase 2Completed
- Sponsor
- Investigación Biomédica para el Desarrollo de Fármacos
- Start
- Jul 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ivermectin Arm with Placebo Arm (2 arms). Primary endpoint: Proportion of participants with no disease progression to severe COVID-19 at 14 days. Started Jul 2020; status: completed.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04407507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04407507.